Winway Health Desk
Troubled AMAG spurns activist’s attempt to rework board as share price...
Activist investor Caligan is hoping to oust four directors on the board of AMAG, the maker of female libido med Vyleesi, for its sluggish...
FDA issues industry guidance for developing amyotrophic lateral sclerosis drugs
The Food and Drug Administration has issued an industry guidance for the development of drugs to treat a notoriously devastating neurodegenerative disease.
On Monday, the...
Dr Aseem Malhotra: Evidence-based medicine has been hijacked
Table of contents
0:00 – 2:07 – Introduction and outline of talk 2:08 – 3:58 – What is evidence-based medicine (EBM)? 3:59 – 9:40 – Case study:...
AbbVie’s premium bid for Allergan isn’t enough for one investor, who’s...
Allergan encountered years of setbacks before AbbVie swooped in this summer to purchase the company for a whopping $63 billion. But one small-time Allergan investor...
Helping people with diabetes avoid emergency care could save NHS GBP3...
Supporting people with diabetes to avoid emergency hospital care could save the NHS as much as £3 billion per year according, to...
Novo prices oral Rybelsus on par with injectable rivals, ending discount...
Monday morning, Bernstein analyst Wimal Kapadia echoed what many industry watchers were probably thinking about Novo Nordisk’s Rybselsus price: “Finally we can stop talking about...
CGM leads to greater improvement in type 1 control than with...
Real-time continuous glucose monitoring (rtCGM) is effective among those with type 1 diabetes, irrespective of how insulin is delivered to the body,...
Torrent, Dr. Reddy’s actions add to cracks in global drug supply chain
Interruptions continue to wreak havoc on the global drug supply as drugmakers respond to the detection of impurities that are produced during manufacturing of...
US approves first oral GLP-1 treatment for type 2 diabetes
The first glucagon-like peptide-1 (GLP-1) receptor agonist in tablet form has been approved for people with type 2 diabetes in the US.Rybelsus,...
FiercePharmaPolitics—Pelosi plan a ‘non-starter’ for Senate GOP, but Trump tweets differently
Welcome to the FiercePharma political roundup, where each Monday we’ll highlight notable developments that could affect how drugmakers operate.
As expected, House Democrats released their...
